EGFR -mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis

Introduction EGFR mutations occur most frequently in patients with lung adenocarcinoma in East Asia. However, the prognostic and therapeutic impact of co-mutational status of EGFR and tumor suppressor genes is not fully understood. This study aims to provide a deeper understanding of lung adenocarcinoma patients with co-mutation of EGFR and tumor suppressor genes. Methods From November 2009 to May 2016, 675 patients with lung adenocarcinoma who underwent complete surgery were included in this study. Samples were collected and pathologically examined. Whole-exome sequencing was performed on 197 samples, while direct sequencing of major driver genes, including EGFR , KRAS , ERBB2 and BRAF and Ion-torrent targeted sequencing of tumor suppressor genes, including TP53 , KEAP1 , MGA , NF1 , RB1 , SMARCA4 and STK11 , were performed on 478 samples. Tumor mutational burden was calculated and survival analyses were performed. Results The frequency of EGFR and TP53 mutation was 409 (60.6%) and 215 (31.9%), respectively. Co-mutation of EGFR and TP53 occured in 151 patients (22.4%), while co-mutation of EGFR and at least one tumor suppressor gene occured in 184 patients (27.3%). Compared with patients with only EGFR mutations, patients with co-mutations of EGFR and TP53 had a higher tumor mutational burden ( p = 0.007) and worse recurrence-free survival ( p = 0.010), while patients with co-mutations of EGFR and at least one tumor suppressor gene had a higher tumor mutational burden ( p = 0.007), worse recurrence-free survival ( p = 0.016) and worse overall survival ( p = 0.018). Conclusions Lung adenocarcinoma patients harboring EGFR and co-mutational tumor suppressor genes should be regarded as a unique subgroup.